Medicinal composition and application thereof

Abstract

The invention discloses a medicinal composition, which comprises two or three of a, b and c, wherein a is long-chain fatty acid compounds of a formula I or plant extract containing the same; b is flavonoid compounds of a formula II or plant extract containing the same; and c is the following alkaloid compounds or plant extract containing the same: N1,N5,N10-tri-(E / Z)-coumaroyl spermidine, 1-O-(beta-D-glucose)-(2S, 3S, 4R)-2N-[(2'R)-2'-hydroxytetracosenoicacid]-octadecylene-3,4-diol, putrescine and indol-3-acetic acid. The medicinal composition of the invention can be used for preparing aromatizing enzyme inhibitor, 5alpha reductase inhibitor, alpha1-adrenergic receptor antagonist, cyclooxygenase-2 inhibitor, prostate-specific antigen (PSA) secretion inhibitor, anti-inflammation medicamentor medicament for resisting prostatic hyperplasia, prostatitis or prostatic cancer.

Description

technical field

[0001] The invention belongs to the field of pharmaceutical compositions, in particular to a pharmaceutical composition and its application. Background technique

[0002] Benign prostatic hyperplasia (BPH) is a common physiological lesion in elderly men. When the lesion causes a series of symptoms such as urinary obstruction, it is called benign prostatic hyperplasia. Autopsy reports of 1075 cases abroad showed that: at the age of 25 to 30, 10% of men could see early benign prostatic hyperplasia lesions under the microscope; as the age increases, the incidence of benign prostatic hyperplasia diagnosed by histology also increases accordingly; By the age of 51 to 60, the incidence rate increases to 75%; by the age of 85, about 90% of men have histological BPH. It can be seen from the above that with the acceleration of population aging in my country, the incidence of benign prostatic hyperplasia caused by old age continues to rise, and benign prostatic hyperpl...

Images